Skip to main content
Erschienen in: World Journal of Pediatrics 3/2024

19.09.2023 | Research Letter

Safety and efficacy of omalizumab for antihistamine-resistant chronic urticaria in children: a case series and literature review

verfasst von: Wei-Fang Zhu, Chen Wang, Jian-Jun Qiao, Lan-Juan Li

Erschienen in: World Journal of Pediatrics | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Excerpt

Chronic urticaria (CU) is a common skin disease characterized by the occurrence of wheals, with or without angioedema, lasting more than 6 weeks. The prevalence of CU is about 0.7% [1], but higher in children, with an incidence of 1.38% [1]. The occurrence of severe pruritus and unpredictable wheals may severely impact patients’ quality of life, cause psychological problems, including sleep disorders and depression, and lead to economic burden due to limitation on daily life and work [2, 3]. A standard-dose, second-generation H1-antihistamine (sgAHs) is the first-line therapy for patients with CU [4]. However, more than one-third of CU patients are insufficiently responsive to H1-antihistamines, even with a dosage four times the standard dose (second line; off-label) [4, 5]. Therefore, add-on treatment should be considered. …
Literatur
1.
Zurück zum Zitat Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75:423–32.CrossRefPubMed Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75:423–32.CrossRefPubMed
2.
Zurück zum Zitat Goncalo M, Gimenez-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226–36.CrossRefPubMed Goncalo M, Gimenez-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226–36.CrossRefPubMed
3.
Zurück zum Zitat Konstantinou GN, Konstantinou GN. Psychiatric comorbidities in children and adolescents with chronic urticaria. World J Pediatr. 2023;19:315–22.CrossRefPubMed Konstantinou GN, Konstantinou GN. Psychiatric comorbidities in children and adolescents with chronic urticaria. World J Pediatr. 2023;19:315–22.CrossRefPubMed
4.
Zurück zum Zitat Zhao Z, Cai T, Chen H, Chen L, Chen Y, Gao X, et al. Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ J. 2021;14:100610.CrossRefPubMedPubMedCentral Zhao Z, Cai T, Chen H, Chen L, Chen Y, Gao X, et al. Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ J. 2021;14:100610.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32:153–60.CrossRefPubMed Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32:153–60.CrossRefPubMed
6.
Zurück zum Zitat Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.CrossRefPubMed Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.CrossRefPubMed
7.
Zurück zum Zitat Gimenez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17:375–85.CrossRefPubMed Gimenez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17:375–85.CrossRefPubMed
8.
Zurück zum Zitat Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.CrossRefPubMed Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.CrossRefPubMed
9.
Zurück zum Zitat Staubach P, Peveling-Oberhag A, Lang BM, Zimmer S, Sohn A, Mann C. Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review. J Dermatolog Treat. 2022;33:1119–22.CrossRefPubMed Staubach P, Peveling-Oberhag A, Lang BM, Zimmer S, Sohn A, Mann C. Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review. J Dermatolog Treat. 2022;33:1119–22.CrossRefPubMed
10.
Zurück zum Zitat Mitra D. A randomized, double-blind, placebo-controlled study of monoclonal anti-IgE antibody omalizumab in the management of pruritus in chronic spontaneous urticaria in the pediatric population. Pediatr Dermatol. 2018;35:712–3. Mitra D. A randomized, double-blind, placebo-controlled study of monoclonal anti-IgE antibody omalizumab in the management of pruritus in chronic spontaneous urticaria in the pediatric population. Pediatr Dermatol. 2018;35:712–3.
11.
Zurück zum Zitat Wang A, Yun Y, Wen Z, Gao Y, Qi S, Zhang Y, et al. Efficacy and safety of omalizumab against chronic spontaneous urticaria: real-world study from China. World Allergy Organ J. 2022;15:100719.CrossRefPubMedPubMedCentral Wang A, Yun Y, Wen Z, Gao Y, Qi S, Zhang Y, et al. Efficacy and safety of omalizumab against chronic spontaneous urticaria: real-world study from China. World Allergy Organ J. 2022;15:100719.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Dekkers C, Alizadeh Aghdam M, de Graaf M, Knulst AC, Meijer Y, van den Reek J, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2021;32:720–6.CrossRefPubMedPubMedCentral Dekkers C, Alizadeh Aghdam M, de Graaf M, Knulst AC, Meijer Y, van den Reek J, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2021;32:720–6.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Song XT, Chen YD, Yu M, Liu B, Zhao ZT, Maurer M. Omalizumab in children and adolescents with chronic urticaria: a 16 week real-world study. Allergy. 2021;76:1271–3.CrossRefPubMed Song XT, Chen YD, Yu M, Liu B, Zhao ZT, Maurer M. Omalizumab in children and adolescents with chronic urticaria: a 16 week real-world study. Allergy. 2021;76:1271–3.CrossRefPubMed
14.
Zurück zum Zitat Ari A, Levy Y, Segal N, Maoz-Segal R, Benor S, Broides A, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. 2020;37:1051–4.CrossRefPubMed Ari A, Levy Y, Segal N, Maoz-Segal R, Benor S, Broides A, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. 2020;37:1051–4.CrossRefPubMed
15.
Zurück zum Zitat Guarracino C, Tomasoni A, Marseglia A, Marseglia GL, Licari A. Real-life data on the effectiveness and safety of omalizumab in adolescents with chronic spontaneous urticaria: a retrospective study. Pediatr Allergy Immunol. 2020;31:79. Guarracino C, Tomasoni A, Marseglia A, Marseglia GL, Licari A. Real-life data on the effectiveness and safety of omalizumab in adolescents with chronic spontaneous urticaria: a retrospective study. Pediatr Allergy Immunol. 2020;31:79.
16.
Zurück zum Zitat Kalugina V, Namazova-Baranova L, Vishneva E, Alekseeva A, Dobrynina E, Levina J, et al. Evaluating the efficacy of omalizumab therapy in a group of adolescents with chronic urticaria in real clinical practice. World Allergy Org J. 2020;13:100316.CrossRef Kalugina V, Namazova-Baranova L, Vishneva E, Alekseeva A, Dobrynina E, Levina J, et al. Evaluating the efficacy of omalizumab therapy in a group of adolescents with chronic urticaria in real clinical practice. World Allergy Org J. 2020;13:100316.CrossRef
17.
Zurück zum Zitat Gabrielli S, Netchiporouk E, Baum S, Greenberger S, Staubach-Renz P, Ben-Shoshan M. Management of Chronic Urticaria in a Pediatric Population. J Allergy Clin Immunol. 2019;143:AB301. CrossRef Gabrielli S, Netchiporouk E, Baum S, Greenberger S, Staubach-Renz P, Ben-Shoshan M. Management of Chronic Urticaria in a Pediatric Population. J Allergy Clin Immunol. 2019;143:AB301. CrossRef
18.
Zurück zum Zitat Kahveci M, Sahiner ÜM, Büyüktiryaki B, Sekerel BE, Soyer O. Omalizumab treatment in children with chronic spontaneous urticaria: efficacy and safety. Allergy Eur J Allergy Clin Immunol. 2019;74:867–8. Kahveci M, Sahiner ÜM, Büyüktiryaki B, Sekerel BE, Soyer O. Omalizumab treatment in children with chronic spontaneous urticaria: efficacy and safety. Allergy Eur J Allergy Clin Immunol. 2019;74:867–8.
19.
Zurück zum Zitat Cekic S, Karali Y, Canitez Y, Sapan N. Omalizumab treatment in childhood chronic urticaria. Allergy. 2018;73:227. Cekic S, Karali Y, Canitez Y, Sapan N. Omalizumab treatment in childhood chronic urticaria. Allergy. 2018;73:227.
20.
Zurück zum Zitat El Bilali J, Gabrielli S, Shand G, Netichoprouk E, Ben-Shoshan M. Omalizumab for management of chronic urticaria in a pediatric population: a case-series. J Allergy Clin Immunol. 2018;141:AB55.CrossRef El Bilali J, Gabrielli S, Shand G, Netichoprouk E, Ben-Shoshan M. Omalizumab for management of chronic urticaria in a pediatric population: a case-series. J Allergy Clin Immunol. 2018;141:AB55.CrossRef
21.
Zurück zum Zitat Staubach P, Peveling-Oberhag A, Jäger M, Lang B, Sohn A, Geppert C, et al. Antihistamine-resistant chronic spontaneous urticaria in children-treatment with omalizumab. Pediatr Dermatol. 2017;34:S50. Staubach P, Peveling-Oberhag A, Jäger M, Lang B, Sohn A, Geppert C, et al. Antihistamine-resistant chronic spontaneous urticaria in children-treatment with omalizumab. Pediatr Dermatol. 2017;34:S50.
22.
Zurück zum Zitat Vishneva E, Namazova-Baranova L, Alekseeva A, Levina J, Kalugina V, Efendieva K, et al. Successful omalizumab treatment in adolescents with chronic urticaria. Allergy. 2018;73:137. Vishneva E, Namazova-Baranova L, Alekseeva A, Levina J, Kalugina V, Efendieva K, et al. Successful omalizumab treatment in adolescents with chronic urticaria. Allergy. 2018;73:137.
23.
Zurück zum Zitat Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33:e13489.CrossRefPubMed Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33:e13489.CrossRefPubMed
24.
Zurück zum Zitat Al-Shaikhly T, Rosenthal JA, Ayars AG, Petroni DH. Omalizumab for chronic urticaria in children younger than 12 years. Annals Allergy Asthma Immunol. 2019;123:208–210e202.CrossRef Al-Shaikhly T, Rosenthal JA, Ayars AG, Petroni DH. Omalizumab for chronic urticaria in children younger than 12 years. Annals Allergy Asthma Immunol. 2019;123:208–210e202.CrossRef
25.
Zurück zum Zitat Petrovicová O, Jesenak M, Kapustova L, Banovcin P. Off-label use of omalizumab for chronic spontaneous urticaria in children younger than 12 years (experience of one centre). Allergy Eur J Allergy Clin Immunol. 2020;75:434–5. Petrovicová O, Jesenak M, Kapustova L, Banovcin P. Off-label use of omalizumab for chronic spontaneous urticaria in children younger than 12 years (experience of one centre). Allergy Eur J Allergy Clin Immunol. 2020;75:434–5.
26.
Zurück zum Zitat Kalugina VG, Vishneva EA, Namazova-Baranova LS. Efficiency of adding omalizumab to standard therapy for children with recurrent spontaneous urticaria: Comparative observational study. Pediatricheskaya Farmakologiya. 2020;17:179–86.CrossRef Kalugina VG, Vishneva EA, Namazova-Baranova LS. Efficiency of adding omalizumab to standard therapy for children with recurrent spontaneous urticaria: Comparative observational study. Pediatricheskaya Farmakologiya. 2020;17:179–86.CrossRef
27.
Zurück zum Zitat Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Sola I, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76:59–70.CrossRefPubMed Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Sola I, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76:59–70.CrossRefPubMed
Metadaten
Titel
Safety and efficacy of omalizumab for antihistamine-resistant chronic urticaria in children: a case series and literature review
verfasst von
Wei-Fang Zhu
Chen Wang
Jian-Jun Qiao
Lan-Juan Li
Publikationsdatum
19.09.2023
Verlag
Springer Nature Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 3/2024
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-023-00760-4

Weitere Artikel der Ausgabe 3/2024

World Journal of Pediatrics 3/2024 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.